Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2023-02-15
2024-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Artificial Intelligent Decision Support for Skin Cancer Diagnostics in Primary Care
NCT06932172
Implementation of Teledermoscopy and Artificial Intelligence
NCT05033678
Diagnostic Precision of the AI Tool Dermalyzer to Identify Malignant Melanomas in Subjects Seeking Primary Care for Melanoma-suspected Cutaneous Lesions
NCT05172232
Improving Skin Cancer Management With Artificial Intelligence (04.17 SMARTI)
NCT04040114
Melanoma Detection in Switzerland With VECTRA
NCT04605822
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this study we will examine the impact of such factors in a real-world setting where we integrate an algorithm in an existing teledermatoscopy platform that is used clinically at a tertiary hospital in Sweden. We will investigate what impact various implementations of AI tool output in relation to human factors have on diagnostic accuracy and management decisions.
Study subjects are recruited at the Department of Dermatology at Karolinska University Hospital and will be asked to rate prospective teledermatoscopic consults with and without AI-support. Each consult will be randomized into one of three workflows with or without one pre-defined implementation of the AI tool. Study subjects are also asked to complete two surveys with demographic information and questions relating to various human factors. Patients participating in the study will be diagnosed outside the study prior to inclusion without any involvement of an AI tool, notably by two experienced dermatologists who do not participate as study subjects.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Workflow 1
Standard of care
No interventions assigned to this group
Workflow 2
Consult with AI assistance
AI assistance
Participants will be informed of the diagnostic probabilities for each of ten differential diagnoses according to the AI tool
Workflow 3
First workflow 1, then workflow 2
AI assistance
Participants will be informed of the diagnostic probabilities for each of ten differential diagnoses according to the AI tool
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AI assistance
Participants will be informed of the diagnostic probabilities for each of ten differential diagnoses according to the AI tool
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Working at a dermatology clinic
* Sufficient knowledge in Swedish
* Written consent to participate
Exclusion Criteria
* Does not wish to participate
* Incomplete answers
* Physicians that are involved in the patients' clinical care relating to the teledermoscopical consult
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Karolinska Institutet
OTHER
Medical University of Vienna
OTHER
Stockholm School of Economics
UNKNOWN
Karolinska University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jan Lapins
MD, PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Karolinska University Hospital
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
960024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.